Podcasts about general medicine and primary care

Guest: Kimberly Narain, MD, MPH, PhD Cost-related medication nonadherence remains a significant but often hidden barrier to effective diabetes care, with out-of-pocket costs preventing patients from accessing essential therapies. Dr. Kimberly Narain joins us to explain why clinicians should look beyond insurance status alone and consider affordability challenges when developing strategies to improve diabetes outcomes. Dr. Narain is an Assistant Professor of Medicine at the David Geffen School of Medicine at UCLA, as well as the Director of Health Services and Health Optimization Research at the Iris Cantor UCLA Women's Health Center. She also spoke about this topic at the 2026 American Diabetes Association Scientific Sessions.

Host: Steve Jackson, PharmD Guest: Souptik Barua, PhD Guest: Emily Johnston, MPH, PhD Can older adults successfully engage with telehealth, wearable technology, and digital health tools to prevent type 2 diabetes? In this conversation with Dr. Steve Jackson, Ds. Emily Johnston and Dr. Souptik Barua discuss emerging insights on how these strategies could improve accessibility and engagement in a high-risk population. Dr. Johnston is a Research Assistant Professor in the Department of Medicine, and Dr. Barua is an Assistant Professor in the Division of Precision Medicine at the NYU Grossman School of Medicine. They presented these findings at the 2026 American Diabetes Association Scientific Sessions.

Guest: Javier Morales, MD, FACP, FACE For patients with obesity and type 2 diabetes (T2D), emerging incretin-based therapies that target multiple metabolic pathways are producing meaningful weight-loss outcomes. To learn more about these care strategies, tune in as Dr. Javier Morales shares key updates from the 2026 American Diabetes Association Scientific Sessions. Dr. Morales is an Associate Clinical Professor of Medicine at the Barbara and Donald Zucker School of Medicine at Hofstra University and Northwell Health.

Host: Charles Turck, PharmD, BCPS, BCCCP Guest: Maggie Emerson, DNP, APRN, PMHNP-BC Guiding patients and caregivers through the fast-moving landscape of digital therapeutics can be a challenging but worthwhile part of providing effective and accessible care. That's why Dr. Charles Turck speaks with Dr. Maggie Emerson about how we can best partner with patients and caregivers around this relatively new treatment in mental health care. Dr. Emerson is a Clinical Associate Professor at the University of Nebraska Medical Center College of Nursing in Omaha.

Host: Matt Birnholz, MD Guest: Abigail Sporer, PhD, MBA At the intersection of expertise, strategy, and collaboration, medical affairs professionals are translating vaccine science into meaningful and actionable insights for healthcare providers. In this candid conversation from the 2026 Medical Affairs Professional Society (MAPS) Annual Meeting, Dr. Matt Birnholz and Dr. Abigail Sporer, Director of US Medical Affairs at CSL Seqirus, discuss the evolving realities of vaccine education, from addressing misinformation to strengthening engagement. Learn more about how medical affairs plays a role in supporting clinicians and improving communication in a complex public health landscape.

Guest: Thomas S. Bottiglieri, D.O. On this episode of Advances in Care, host Erin Welsh sits down with Dr. Thomas Bottiglieri, Chief of the Primary Care Sports Medicine Division at NewYork-Presbyterian and Columbia, to discuss the evolving landscape of concussion care—from prevalence to emerging diagnostic breakthroughs. With over 2 million estimated concussions occurring annually in the United States and many of them affecting young athletes, Dr. Bottiglieri and his colleagues have sought to develop a more accurate and accessible way to objectively diagnose concussion. While a single injury may not cause long-term issues, research shows that repeated head trauma—and lack of proper care—can lead to premature neurodegeneration. During their research to improve diagnostic measures, Dr. Bottiglieri and his team discovered a biomarker associated with severe concussions: a subtle tremor of the head and neck that becomes amplified when a concussed patient tries to visually focus on a target. This discovery led to the development of ProScope, an innovative eye-tracking software tool that measures head and neck stability and can detect the diagnostic biomarker with over 80% sensitivity. With the advent of these tools, clinicians can now, for the first time, objectively measure concussion. A former competitive athlete himself, Dr. Bottiglieri hopes that the ProScope tool …

CME credits: 0.25 Valid until: 19-03-2027 Claim your CME credit at https://reachmd.com/programs/cme/dka-new-consensus-practice/50979/ If widespread use of continuous ketone monitoring (CKM) devices is to be safe and effective in reducing the occurrence of diabetic ketoacidosis (DKA), it is important to establish clear ketone thresholds which notify CKM users when action on their part is required. In preparation for availability and use in practice, and in the absence of substantial evidence that can identify appropriate ketone thresholds for CKM use, an international panel of experts in the management of DKA developed objective practical recommendations on how this novel diabetes technology could improve outcomes for individuals at risk of DKA.=

CME credits: 0.25 Valid until: 13-03-2027 Claim your CME credit at https://reachmd.com/programs/cme/case-selecting-therapy-cushing-syndrome/50063/ Cushing syndrome has seen exciting advances over the last couple of years, but how do they translate into improved patient care? Let's dig into a couple of cases and discuss! =

CME credits: 0.25 Valid until: 06-03-2027 Claim your CME credit at https://reachmd.com/programs/cme/breaking-ground-2025-milestones-in-cushing-syndrome-and-looking-forward-to-2026/50059/ 2025 delivered an expanded approval for Cushing syndrome for one agent, a complete response letter for another, and deeper insights on the prevalence of Cushing syndrome (or hypercortisolism) in people with difficult-to-control metabolic conditions. 2026 promises to be jam packed with further insights on Cushing syndrome prevalence and data for emerging drugs. Join our faculty as they review advances from 2025 and look ahead to what's coming in 2026.=

Host: Charles Turck, PharmD, BCPS, BCCCP Guest: George Grossberg, MD Guest: Angela Sanford, MD, CMD Nearly half of patients living with dementia due to Alzheimer's disease will experience agitation during the course of illness.1 In June 2025, expert panel recommendations on identifying and managing agitation in Alzheimer's dementia were published in Postgraduate Medicine. Learn more about these recommendations as Dr. Charles Turck, Dr. George Grossberg, and Dr. Angela Sanford explore how clinicians can implement them in practice. Dr. Grossberg is the Inaugural Henry and Amelia Nasrallah Endowed Professor as well as the Director of the Division of Geriatric Psychiatry and Behavioral Neuroscience at the Saint Louis University School of Medicine. Dr. Sanford is a Professor in the Division of Geriatric Medicine in the Department of Internal Medicine at the Saint Louis University School of Medicine. Drs. Grossberg and Sanford are paid consultants of Otsuka Pharmaceutical Development & Commercialization, Inc. The expert panel and subsequent publication were sponsored by Otuska and Lundbeck -- not an independent entity. References: Grossberg GT, Sanford A, Montano CB, et al. A US-based practitioner's guide to diagnosis, evaluation, and evidence-based treatment of agitation in Alzheimer's dementia - recommendations of an expert, multispecialty advisory panel. Postgrad Med. 2025;137(6):469–485.

Host: Stephanie Christenson, MD Guest: Diego Maselli, MD, FCCP COPD is increasingly recognized as a heterogeneous disease, and for a subset of patients, type 2 inflammation plays a meaningful role in exacerbation risk and treatment response. Given that, Drs. Stephanie Christenson and Diego Maselli come together to examine how insights into the pathobiology of type 2 inflammation can directly inform clinical decision making in COPD. Specifically, they discuss the practical use of blood eosinophil counts to phenotype patients, assess risk, and guide therapy selection within the context of GOLD 2025 and 2026 guidance. Dr. Christenson is an Associate Professor at the University of California San Francisco in the Division of Pulmonary, Critical Care, Allergy, and Sleep Medicine, and Dr. Maselli is a Professor of Medicine at the Long School of Medicine at UT Health in San Antonio. This episode of Deep Breaths: Updates from CHEST was supported by a non-promotional, non-CME educational program brought to you by CHEST in collaboration with and sponsored by GSK.

Presenter: Sally E. Wenzel, MD, ATSF Given that severe asthma management is entering a new era of biologically driven precision, Dr. Sally Wenzel joins us to discuss the complexity within Type 2 inflammation and the limitations of relying on a single biomarker assessment. She also differentiates childhood-onset allergic asthma from adult-onset disease, underscoring how age of onset—along with underlying biology—can inform therapeutic strategy. Dr. Wenzel serves as the Director of the Asthma Institute at UPMC, and she spoke about this topic at the 2026 American Academy of Allergy, Asthma, and Immunology Annual Meeting.

Guest: Ravi Kalhan, MD Guest: MeiLan K. Han, MD, MS For patients with chronic obstructive pulmonary disease (COPD), exacerbations are early indicators of disease progression—not just isolated events. In this expert-led discussion, Drs. Ravi Kalhan and Meilan Han break down the latest GOLD updates, explain how to use eosinophil counts to guide treatment, and discuss when to consider adding biologic therapy. Dr. Kalhan is the Louis A. Simpson Professor of Pulmonary Medicine and Director of the Asthma and COPD Program at Northwestern Medicine in Chicago. Dr. Han is a Professor of Medicine and Chief of the Division of Pulmonary and Critical Care at the University of Michigan Health in Ann Arbor. This episode of Deep Breaths: Updates from CHEST was supported by a non-promotional, non-CME educational program brought to you by CHEST in collaboration with and sponsored by GSK.

Guest: Lauren Osborne, M.D. Lauren Osborne, M.D., a reproductive psychiatrist at NewYork-Presbyterian and Weill Cornell Medicine and vice chair for clinical research for the Department of Obstetrics and Gynecology, discusses her research into the biological basis of postpartum depression. In a recent study, Dr. Osborne and her team were the first to analyze the entire metabolic pathway of progesterone, measuring both positive and negative allosteric modulators of the GABAA receptor throughout pregnancy and ultimately identifying a potential biomarker to predict risk. They are continuing to study and build upon these findings, with the goal of enabling better prediction and treatment options to address, or even prevent, postpartum depression. © 2026 NewYork-Presbyterian

CME credits: 1.00 Valid until: 06-01-2027 Claim your CME credit at https://reachmd.com/programs/cme/oh-the-hats-youll-wear-the-many-modalities-of-pediatric-obesity-management/39966/ On-demand webcast of expert faculty presentation on the diagnosis and management of obesity for pediatric patients, including communication and patient-centered care strategies to improve health outcomes.=

CME credits: 1.00 Valid until: 31-12-2026 Claim your CME credit at https://reachmd.com/programs/cme/tailoring-treatment-can-you-select-the-best-therapy/51483/ This educational series guides clinicians through the full continuum of inflammatory bowel disease (IBD) care, from diagnosis to long-term management. Learners begin by distinguishing IBD from other gastrointestinal disorders and assessing disease severity, then explore the underlying immunopathogenesis to understand therapeutic targets. The program emphasizes individualized treatment decisions, practical case reviews, and a treat-to-target approach that advances patients toward sustained remission. Learn to evaluate treatment success and make informed choices about switching or maintaining therapy to achieve optimal outcomes.

CME credits: 1.00 Valid until: 31-12-2026 Claim your CME credit at https://reachmd.com/programs/cme/ibd-immunopathogenesis-do-you-know-what-youre-blocking/51482/ This educational series guides clinicians through the full continuum of inflammatory bowel disease (IBD) care, from diagnosis to long-term management. Learners begin by distinguishing IBD from other gastrointestinal disorders and assessing disease severity, then explore the underlying immunopathogenesis to understand therapeutic targets. The program emphasizes individualized treatment decisions, practical case reviews, and a treat-to-target approach that advances patients toward sustained remission. Learn to evaluate treatment success and make informed choices about switching or maintaining therapy to achieve optimal outcomes.

CME credits: 1.00 Valid until: 31-12-2026 Claim your CME credit at https://reachmd.com/programs/cme/case-review-targets-are-metcan-you-stick-the-landing/51488/ This educational series guides clinicians through the full continuum of inflammatory bowel disease (IBD) care, from diagnosis to long-term management. Learners begin by distinguishing IBD from other gastrointestinal disorders and assessing disease severity, then explore the underlying immunopathogenesis to understand therapeutic targets. The program emphasizes individualized treatment decisions, practical case reviews, and a treat-to-target approach that advances patients toward sustained remission. Learn to evaluate treatment success and make informed choices about switching or maintaining therapy to achieve optimal outcomes.

CME credits: 1.00 Valid until: 31-12-2026 Claim your CME credit at https://reachmd.com/programs/cme/switching-strategies-switch-or-staywhats-your-call/51487/ This educational series guides clinicians through the full continuum of inflammatory bowel disease (IBD) care, from diagnosis to long-term management. Learners begin by distinguishing IBD from other gastrointestinal disorders and assessing disease severity, then explore the underlying immunopathogenesis to understand therapeutic targets. The program emphasizes individualized treatment decisions, practical case reviews, and a treat-to-target approach that advances patients toward sustained remission. Learn to evaluate treatment success and make informed choices about switching or maintaining therapy to achieve optimal outcomes.

CME credits: 1.00 Valid until: 31-12-2026 Claim your CME credit at https://reachmd.com/programs/cme/remission-can-you-prove-it/51486/ This educational series guides clinicians through the full continuum of inflammatory bowel disease (IBD) care, from diagnosis to long-term management. Learners begin by distinguishing IBD from other gastrointestinal disorders and assessing disease severity, then explore the underlying immunopathogenesis to understand therapeutic targets. The program emphasizes individualized treatment decisions, practical case reviews, and a treat-to-target approach that advances patients toward sustained remission. Learn to evaluate treatment success and make informed choices about switching or maintaining therapy to achieve optimal outcomes.

CME credits: 1.00 Valid until: 31-12-2026 Claim your CME credit at https://reachmd.com/programs/cme/treat-to-target-are-we-there-yet/51485/ This educational series guides clinicians through the full continuum of inflammatory bowel disease (IBD) care, from diagnosis to long-term management. Learners begin by distinguishing IBD from other gastrointestinal disorders and assessing disease severity, then explore the underlying immunopathogenesis to understand therapeutic targets. The program emphasizes individualized treatment decisions, practical case reviews, and a treat-to-target approach that advances patients toward sustained remission. Learn to evaluate treatment success and make informed choices about switching or maintaining therapy to achieve optimal outcomes.

CME credits: 1.00 Valid until: 31-12-2026 Claim your CME credit at https://reachmd.com/programs/cme/case-review-can-you-crack-this-ibd-case/51484/ This educational series guides clinicians through the full continuum of inflammatory bowel disease (IBD) care, from diagnosis to long-term management. Learners begin by distinguishing IBD from other gastrointestinal disorders and assessing disease severity, then explore the underlying immunopathogenesis to understand therapeutic targets. The program emphasizes individualized treatment decisions, practical case reviews, and a treat-to-target approach that advances patients toward sustained remission. Learn to evaluate treatment success and make informed choices about switching or maintaining therapy to achieve optimal outcomes.

CME credits: 1.00 Valid until: 31-12-2026 Claim your CME credit at https://reachmd.com/programs/cme/diagnosing-ibd-is-it-ibd-or-something-else-can-you-tell/51480/ This educational series guides clinicians through the full continuum of inflammatory bowel disease (IBD) care, from diagnosis to long-term management. Learners begin by distinguishing IBD from other gastrointestinal disorders and assessing disease severity, then explore the underlying immunopathogenesis to understand therapeutic targets. The program emphasizes individualized treatment decisions, practical case reviews, and a treat-to-target approach that advances patients toward sustained remission. Learn to evaluate treatment success and make informed choices about switching or maintaining therapy to achieve optimal outcomes.

CME credits: 1.00 Valid until: 31-12-2026 Claim your CME credit at https://reachmd.com/programs/cme/severity-assessment-can-you-pin-the-stage-on-the-patient/51481/ This educational series guides clinicians through the full continuum of inflammatory bowel disease (IBD) care, from diagnosis to long-term management. Learners begin by distinguishing IBD from other gastrointestinal disorders and assessing disease severity, then explore the underlying immunopathogenesis to understand therapeutic targets. The program emphasizes individualized treatment decisions, practical case reviews, and a treat-to-target approach that advances patients toward sustained remission. Learn to evaluate treatment success and make informed choices about switching or maintaining therapy to achieve optimal outcomes.

CME credits: 1.00 Valid until: 16-10-2026 Claim your CME credit at https://reachmd.com/programs/cme/primary-care-for-the-brain-prevention-and-early-detection-of-cognitive-decline/39897/ In this on-demand webcast, leading experts in brain health provide guidance for patient education, discussion, and management geared toward HCPs in primary care who are at the forefront of an aging population at risk of cognitive decline trying to plan for its future and for whom brain health is a topic of uttermost importance.=

CME credits: 1.00 Valid until: 17-12-2026 Claim your CME credit at https://reachmd.com/programs/cme/are-you-on-top-of-pediatric-atopic-dermatitis-expert-guidance-for-leveraging-the-latest-advances-in-systemic-therapy/54260/ On-demand webcast of expert faculty presentation on the disease burden of pediatric atopic dermatitis and strategies for helping patients achieve disease control with systemic therapy.=

Host: Jennifer Caudle, DO Guest: Wendy Wright, DNP, FNP-BC, ANP-BC Randomized controlled trials have shown data supporting the safety and efficacy of cell-based influenza vaccines in adults and children.1-4 However, effectiveness studies have historically relied on outcomes based on clinical diagnosis of influenza-like illness rather than test-confirmed influenza.5 Test-confirmed influenza outcomes provide a more specific evaluation of influenza vaccine effectiveness and can help reveal the clinical differences between cell-based versus egg-based vaccines.6 A retrospective test-negative real-world study including more than 106,000 patients compared the cell-based vaccine with egg-based vaccines.7 Dr. Jennifer Caudle sits down with Dr. Wendy Wright to review the key findings from this analysis and their implications. Dr. Wright is a board-certified adult and family nurse practitioner based out of Amherst, New Hampshire as well as the owner of Wright and Associates Family Healthcare. References: FLUCELVAX. Package insert. Seqirus Inc. Bart S, Cannon K, Herrington D, et al. Immunogenicity and safety of a cell culture-based quadrivalent influenza vaccine in adults: a phase III, double-blind, multicenter, randomized, non-inferiority study. Hum Vaccin Immunother. 2016;12(9):2278–88. doi:10.1080/21645515.2016.1182270. Frey S, Vesikari T, Szymczakiewicz-Multanowska A, et al. Clinical efficacy of cell culture-derived and egg-derived inactivated subunit influenza vaccines in healthy adults. Clin Infect Dis. 2010;51(9):997–1004. doi:10.1086/656578. Diez-Domingo J, de Martino M, Lopez …

CME credits: 1.00 Valid until: 02-12-2026 Claim your CME credit at https://reachmd.com/programs/cme/future-proofing-in-hae-advances-in-long-term-prophylaxis-to-prevent-attacks-and-improve-quality-of-life/54448/ On-demand webcast with expert faculty presentation on addressing the unmet needs and optimizing treatment for hereditary angioedema (HAE), including long-term prophylaxis therapy, for patients with HAE.=

Host: Peter Buch, MD, FACG, AGAF, FACP Guest: Aasma Shaukat, MD, MPH Blood-based colorectal cancer screening is entering a new era with FDA-approved and emerging tests like Shield and Simple Screen. Alongside updated stool-based options such as Cologuard Plus and CRC-PREVENT, clinicians now have a broader landscape of noninvasive tools to consider and discuss with their patients. Joining Dr. Peter Buch to talk about current recommendations and potential future directions for colorectal cancer screening is Dr. Aasma Shaukat. Dr. Shaukat is the Robert M. and Mary H. Glickman Professor of Medicine and a Professor of Population Health at NYU Grossman School of Medicine, as well as the Director of Outcomes Research in the Division of Gastroenterology and Hepatology at NYU Langone Health. She's also a co-author of a recent review on blood tests for colorectal cancer.

CME credits: 0.25 Valid until: 18-11-2026 Claim your CME credit at https://reachmd.com/programs/cme/engaging-your-patient-shared-decision-making-in-hf-with-lvef40/29910/ Enhance your ability to apply shared decision-making in patients with HF and LVEF ≥40%. Through real-world clinical vignettes, Dr. Scott Solomon illustrates how to uncover patient goals, clearly communicate risks and benefits, and build collaborative treatment plans. The session emphasizes early use of SGLT2 inhibitors and finerenone to reduce hospitalizations, improve quality of life, and optimize long-term outcomes. =

CME credits: 0.50 Valid until: 07-11-2026 Claim your CME credit at https://reachmd.com/programs/cme/updates-in-major-depressive-disorder-with-insomnia/36556/ Approximately 75% to 90% of patients with depression experience insomnia. This means that a very significant portion of individuals struggling with depression also have difficulty sleeping. Join Drs. Michael Thase and Andrew Krystal for this expert discussion to learn about the most recent data presented at the Psych Congress 2025 in San Diego on emerging therapies, such as the selective OX2R antagonists to treat major depressive disorder with insomnia. =

CME credits: 1.00 Valid until: 30-10-2026 Claim your CME credit at https://reachmd.com/programs/cme/breaking-the-cycle-prioritizing-weight-loss-to-improve-osa-management/48715/ On-demand webcast of expert faculty presentation on the connection between obstructive sleep apnea (OSA) and obesity, including strategies for prioritizing weight loss to improve OSA management among select patients. =

CME credits: 0.25 Valid until: 30-10-2026 Claim your CME credit at https://reachmd.com/programs/cme/are-all-vmat2s-the-same-data-driven-treatment-decisions-for-tardive-dyskinesia/36174/ Tardive Dyskinesia (TD) is an involuntary movement disorder that can develop as a side effect of taking antipsychotic and other medications. Currently there are 2 FDA approved VMAT2 inhibitors for treating TD. Join Drs. Cristoph U. Correll and Jonathan M. Meyer for this expert discussion on the most recent data presented at the Psych Congress 2025 in San Diego on VMAT2 inhibitors for the treatment of TD.=

CME credits: 1.00 Valid until: 21-10-2026 Claim your CME credit at https://reachmd.com/programs/cme/global-perspectives-on-data-in-type-2-diabetes-congress-to-clinic-insights/36231/ On-demand webcast with expert faculty presentation highlighting key studies in diabetes from the 2025 American Diabetes Association and European Association for the Study of Diabetes annual meetings.=

CME credits: 1.00 Valid until: 21-10-2026 Claim your CME credit at https://reachmd.com/programs/cme/global-perspectives-on-new-data-in-type-2-diabetes-congress-to-clinic-insights-from-ada-and-easd-2025/36231/ On-demand webcast with expert faculty presentation highlighting key studies in diabetes from the 2025 American Diabetes Association and European Association for the Study of Diabetes annual meetings.=

CME credits: 1.00 Valid until: 22-10-2026 Claim your CME credit at https://reachmd.com/programs/cme/endovoice-live-endometriosisa-chronic-burden-of-reproductive-years/37176/ This dynamic symposium will guide clinicians through a modern, patient-centered approach to endometriosis care. Faculty will explore how early diagnosis can improve physical and psychosocial outcomes, examine tools to advance equity and shared decision-making, and evaluate the latest evidence for GnRH antagonists as a nonsurgical treatment strategy. The session concludes with a patient perspective that illustrates how lived experience can inform more patient-centered, multidisciplinary care that incorporates medical treatment and shared decision-making. =

CME credits: 1.00 Valid until: 20-10-2026 Claim your CME credit at https://reachmd.com/programs/cme/diagnosing-and-treating-ibs-it-begins-with-one-simple-question/36607/ Presented at the 21st Annual Women's Health Annual Visit (WHAV 2025), this session reviews strategies for diagnosing and treating irritable bowel syndrome (IBS), with a focus on distinguishing IBS-C from IBS-D. Faculty explore the burden of disease, stigma, and the importance of a positive diagnostic strategy using Rome IV criteria, supported by history, physical examination, and selective testing. Treatment approaches include lifestyle changes, pharmacologic interventions, and brain-gut behavioral therapies. =

CME credits: 1.00 Valid until: 15-10-2026 Claim your CME credit at https://reachmd.com/programs/cme/womens-sleep-health-addressing-gaps-in-osa-diagnosis-and-treatment-across-life-stages/36099/ This WHAV 2025 session addresses obstructive sleep apnea (OSA) in women, highlighting how phenotype and risk factors shift across life stages. Experts discuss how varying phenotypes contribute to delayed diagnosis and review screening tools, referral strategies, evidence linking OSA to cardiometabolic risks in menopause and pregnancy and available treatment options. The program underscores the importance of a precision medicine approach informed by phenotype, hormonal status, and patient goals at each stage of a woman's life.=

Host: Peter Buch, MD, FACG, AGAF, FACP Guest: Alexa Weingarden, MD PhD Probiotic use in gastroenterology remains a complex and evolving topic, shaped by variable evidence and growing patient demand. Dr. Peter Buch sits down with Dr. Alexa Weingarden to review current data, discuss distinctions between probiotic-related therapies, and explore the clinical utility of microbiome testing. Dr. Weingarden is an Assistant Professor of Gastroenterology, Hepatology, and Nutrition at the University of Minnesota Medical School.

Host: Peter Buch, MD, FACG, AGAF, FACP Guest: David Levinthal, MD, PhD Cyclic vomiting syndrome (CVS) is often underdiagnosed in adults due to its episodic nature and symptom overlap with other conditions. Dr. David Levinthal joins Dr. Peter Buch to explore key diagnostic criteria, key differences between CVS and cannabinoid hyperemesis syndrome (CHS), and evidence-based treatment strategies. Dr. Levinthal is the Director of the UPMC Neurogastroenterology and Motility Center and an Associate Professor of Medicine at the University of Pittsburgh School of Medicine.

CME credits: 1.00 Valid until: 14-09-2026 Claim your CME credit at https://reachmd.com/programs/cme/psoriasis-and-obesity-going-pound-for-pound-on-comprehensive-patient-centered-management/39671/ On-demand webcast of expert faculty presentation on the key connection between psoriasis and obesity, including comprehensive treatment strategies that consider outcomes improvement for both diseases.=

Host: Peter Buch, MD, FACG, AGAF, FACP Guest: Paul Kwo, MD While sometimes overlooked, minimally elevated liver tests may signal early liver disease or non-hepatic conditions like thyroid dysfunction. As a result, interpreting ALT and AST thresholds, assessing metabolic risk, and reviewing lifestyle factors can help shape a focused diagnostic approach and reduce liver-related complications. Joining Dr. Peter Buch to provide insights into the evaluation of minimally elevated liver tests is Dr. Paul Kwo, who's a Professor of Medicine and Director of Hepatology at Stanford University.

Host: Ryan Quigley The World Health Organization's new Integrated Lung Health Resolution is the first to explicitly include lung cancer within a global lung health framework. In this AudioAbstract, ReachMD's Ryan Quigley explains what this means for screening, early diagnosis, care pathways, and equitable access to treatment.

Guest: Francis Farraye, MD Host: Peter Buch, MD, FACG, AGAF, FACP A 2025 update to the American College of Gastroenterology (ACG)'s guideline on preventive care in inflammatory bowel disease (IBD) includes key changes impacting vaccine recommendations, dermatologic screening, and care coordination. Dr. Peter Buch sits down with Dr. Francis Farraye, lead author of this guideline, to highlight what clinicians need to know. Dr. Farraye is a Professor of Medicine and the Director of the Inflammatory Bowel Disease Center at the Mayo Clinic in Jacksonville, Florida

Host: Peter Buch, MD, FACG, AGAF, FACP Guest: Iris Wang, M.D. From symptom trackers to multidisciplinary app-based platforms, evidence-based digital therapeutics are expanding access to brain-gut behavioral care for patients with irritable bowel syndrome (IBS) and inflammatory bowel disease (IBD). Dr. Peter Buch sits down with Dr. Iris Wang to discuss the spectrum of available tools and explore strategies for aligning them with individual patient needs. Dr. Wang is an Associate Professor of Medicine and the Associate Program Director of the Gastroenterology Fellowship at the Mayo Clinic in Rochester, Minnesota.

CME credits: 0.50 Valid until: 21-08-2026 Claim your CME credit at https://reachmd.com/programs/cme/risk-reduction-with-glp-1-ras-in-individuals-with-ascvd-and-t2d-2025-update/36474/ Subcutaneously-administered GLP-1 RAs have demonstrated cardiovascular and renal risk reduction in individuals with type 2 diabetes at high ASCVD risk; they are recommended in the 2025 ADA Standards of Care as part of the comprehensive approach to cardiovascular and kidney risk reduction. Many individuals with type 2 diabetes are reluctant to initiate or refuse injectable therapy. Oral GLP-1 RA therapy has demonstrated robust reductions in A1C and in body weight; in addition, the cardiovascular safety of oral GLP-1 RA therapy has been established in individuals with T2D and high cardiovascular risk. Until recently, there has been an unmet need to determine the cardiovascular efficacy of this oral therapy in patients at high cardiovascular risk—for example, in those individuals with ASCVD, CKD, or both. Dr. Silvio Inzucchi and Dr. Darren McGuire will review trials with injectable GLP-1 RAs in individuals with T2D and high ASCVD risk, and discuss the recent clinical trial evidence in this population with oral GLP-1 RA therapy and the implications for patient management. =

CME credits: 0.50 Valid until: 21-08-2026 Claim your CME credit at https://reachmd.com/programs/cme/risk-reduction-with-glp-1-ras-in-individuals-with-ascvd-and-t2d-2025-update/36474/ Subcutaneously-administered GLP-1 RAs have demonstrated cardiovascular and renal risk reduction in individuals with type 2 diabetes at high ASCVD risk; they are recommended in the 2025 ADA Standards of Care as part of the comprehensive approach to cardiovascular and kidney risk reduction. Many individuals with type 2 diabetes are reluctant to initiate or refuse injectable therapy. Oral GLP-1 RA therapy has demonstrated robust reductions in A1C and in body weight; in addition, the cardiovascular safety of oral GLP-1 RA therapy has been established in individuals with T2D and high cardiovascular risk. Until recently, there has been an unmet need to determine the cardiovascular efficacy of this oral therapy in patients at high cardiovascular risk—for example, in those individuals with ASCVD, CKD, or both. Dr. Silvio Inzucchi and Dr. Darren McGuire will review trials with injectable GLP-1 RAs in individuals with T2D and high ASCVD risk, and discuss the recent clinical trial evidence in this population with oral GLP-1 RA therapy and the implications for patient management. =

Host: Jennifer Caudle, DO Guest: Johanna Finkle, MD, FACOG As GLP-1 therapies grow in popularity for weight management and diabetes, an unexpected consequence has emerged: a rise in unplanned pregnancies due to reduced oral contraceptive effectiveness. Dr. Jennifer Caudle sits down with Dr. Johanna Finkle, a weight loss specialist and OB/GYN at the University of Kansas Health System, to explore the mechanisms behind this trend and outline practical, long-acting contraceptive alternatives that maintain efficacy during GLP-1 use.

Host: Peter Buch, MD, FACG, AGAF, FACP Guest: Michael Camilleri, MD GLP-1 receptor agonists are revolutionizing treatment for diabetes and obesity, but their impact on the gastrointestinal tract demands careful clinical attention. Dr. Peter Buch is joined by Dr. Michael Camilleri, Professor of Medicine at the Mayo Foundation for Medical Education and Research in Rochester, Minnesota, to discuss key findings on gastrointestinal side effects, procedural risks, and the impacts of GLP-1 receptor agonists on the fields of gastroenterology and hepatology.

Host: Peter Buch, MD, FACG, AGAF, FACP Guest: Michael Camilleri, MD GLP-1 receptor agonists are revolutionizing treatment for diabetes and obesity, but their impact on the gastrointestinal tract demands careful clinical attention. Dr. Peter Buch is joined by Dr. Michael Camilleri, Professor of Medicine at the Mayo Foundation for Medical Education and Research in Rochester, Minnesota, to discuss key findings on gastrointestinal side effects, procedural risks, and the impacts of GLP-1 receptor agonists on the fields of gastroenterology and hepatology.